Jakavi 5mg Tablet

About Jakavi 5mg Tablet

Jakavi 5mg Tablet contains Ruxolitinib, a targeted kinase inhibitor used to treat certain blood and bone marrow disorders, including myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD) in adults and children aged 12 years and older who have not responded adequately to steroid or other systemic therapies. Ruxolitinib works by blocking abnormal signaling pathways involved in excessive blood cell production and inflammation, helping to reduce symptoms such as enlarged spleen, fatigue, night sweats, and other disease-related complications. The dosage of Jakavi 5mg Tablet is individualized based on factors such as body weight, blood counts, medical condition, and treatment response. Patients should not take this medication if they are allergic to Ruxolitinib or any of its ingredients. Before starting treatment, it is important to inform your healthcare provider about any history of tuberculosis, hepatitis B or C, liver disease, kidney problems, or low blood cell counts. Common side effects may include headache, dizziness, bruising, swelling, anemia, and reduced platelet levels, while signs of infection, unusual bleeding, or persistent fever should be reported immediately. Regular blood tests and medical monitoring are essential during treatment to ensure safety and effectiveness. Jakavi 5mg Tablet is widely used in modern hematology for the long-term management of complex blood disorders, helping improve symptom control and overall quality of life.